INNORYOS
Visco booster with dual effect based on hyaluronic acid combined with niacinamide.
Dual effect
References:
1 Hummer, C.D., Angst, F., Ngai, W. et al. High molecular weight Intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord 21, 702 (2020). https://doi.org/10.1186/s12891-020-03729-w
2 Ogata S, Takeuchi M, Teradaira S, Yamamoto N, Iwata K, Okumura K, Taguchi H. Radical scavenging activities of niacin related compounds. Biosci Biotechnol Biochem. 2002 Mar;66(3):641-5. doi: 10.1271/bbb.66.641. PMID: 12005062
3 Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996 Jul; 45(7):330-4. doi: 10.1007/BF02252945. PMID: 8841834
4 Atlantic Bone Screen, assigned by ALBOMED GmbH. In-vitro evaluation of the anti-hypertrophic effect of 1 product on rat chondrocytes. 2019
The first visco booster
The first visco booster for osteoarthritis patients with dual effect of hyaluronic acid and niacinamide (antioxidative effect, limits inflammation) shows best overall functional behavior for dynamic activities:
- Counterbalances the deleterious effect of osteoarthritis on synovial fluid
- Reinforces the gel with unique antioxidant properties
- Exhibits a high resistance to oxidative degradation
- Creates van-der-Waals bonds between hyaluronic acid chains for cross-stabilization
- Offers exceptional lubricating and shock-absorbing properties, resulting in optimal protection of the articular cartilage
Altogether, INNORYOS® maximizes the osteoarthritis treatment outcomes.
Data table
Below you will find the specification of the INNORYOS® product line, including the color coding that helps to easily distinguish between the different concentrations.
Specification |
INNORYOS® |
|---|---|
Concentration |
2.2 % hyaluronic acid, 1.5 % niacinamide |
Molecular weight* (MDa) |
1.2–2.2 |
Viscosity* (mPas) |
370 000 |
Volume (ml) |
2.0 |
Forms of therapy |
1 to 5 injections |
Storage |
2–25 °C |